Eaton Vance Worldwide Health Sci R (ERHSX)
14.50
-0.08 (-0.55%)
USD |
Aug 16 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.41% | 1.088B | 0.00% | 32.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -53.35M | -2.14% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies principally engaged in the discovery, development, production or distribution of products related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies. It has a policy of investing at least 25% of its assets in investments in the medical research and health care industry. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | ETHSX |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Eaton Vance |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Jason Kritzer | 6.09 yrs |
| Samantha Pandolfi | 6.09 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
60
-53.35M
-3.337B
Category Low
7.804B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of July 31, 2022
Performance Versus Category
As of August 15, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of August 15, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Johnson & Johnson | 8.61% | 167.57 | 0.89% |
| UnitedHealth Group Inc | 7.94% | 546.12 | 0.27% |
| AbbVie Inc | 6.20% | 142.55 | 0.18% |
| Eli Lilly and Co | 5.52% | 310.31 | -1.16% |
|
Roche Holding AG
|
5.07% | -- | -- |
| Thermo Fisher Scientific Inc | 4.62% | 602.11 | -0.39% |
|
AstraZeneca PLC
|
4.55% | -- | -- |
| Novo Nordisk A/S ADR | 4.28% | 105.32 | -0.99% |
| Bristol-Myers Squibb Co | 4.03% | 74.13 | -0.54% |
| Danaher Corp | 3.70% | 300.48 | -0.62% |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies principally engaged in the discovery, development, production or distribution of products related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies. It has a policy of investing at least 25% of its assets in investments in the medical research and health care industry. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | ETHSX |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Eaton Vance |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Jason Kritzer | 6.09 yrs |
| Samantha Pandolfi | 6.09 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (8-15-22) | 0.00% |
| 30-Day SEC Yield (4-30-10) | Upgrade |
| 7-Day SEC Yield (5-25-10) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 27.16 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of June 30, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 9/8/2003 |
| Last Annual Report Date | 8/31/2021 |
| Last Prospectus Date | 1/1/2022 |
| Share Classes | |
| ECHSX | C |
| EIHSX | Inst |
| ETHSX | A |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |